Cargando…

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment

BACKGROUND: A high proportion of people receiving both oral and injectable opioid agonist treatment report concurrent use of stimulants (i.e. cocaine and or amphetamines), which has been associated with higher rates of continued illicit opioid use and treatment dropout. A recent randomized controlle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palis, Heather, Marchand, Kirsten, Peachey, Gerald “ Spike”, Westfall, Jordan, Lock, Kurt, MacDonald, Scott, Jun, Jennifer, Bojanczyk-Shibata, Anna, Harrison, Scott, Marsh, David C., Schechter, Martin T., Oviedo-Joekes, Eugenia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444161/ https://www.ncbi.nlm.nih.gov/pubmed/34530878 http://dx.doi.org/10.1186/s13011-021-00399-2

Ejemplares similares

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
por: Palis, Heather, et al.
Publicado: (2021)

Men’s and women’s response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder
por: Palis, Heather, et al.
Publicado: (2017)

The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC
por: Dobischok, Sophia, et al.
Publicado: (2023)

Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment
por: Marchand, Kirsten, et al.
Publicado: (2020)

Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment
por: Marchand, Kirsten, et al.
Publicado: (2012)

The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2015)

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder()
por: Palis, Heather, et al.
Publicado: (2018)

The Role of Gender in Factors Associated With Addiction Treatment Satisfaction Among Long-Term Opioid Users
por: Marchand, Kirsten, et al.
Publicado: (2015)

Patient-centred care for addiction treatment: a scoping review protocol
por: Marchand, Kirsten, et al.
Publicado: (2018)

Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review
por: Marchand, Kirsten, et al.
Publicado: (2019)

Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2014)

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study
por: Dobischok, Sophia, et al.
Publicado: (2022)

Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2019)

Feasibility of Applying the Life History Calendar in a Population of Chronic Opioid Users to Identify Patterns of Drug Use and Addiction Treatment
por: Fikowski, Jill, et al.
Publicado: (2014)

“As long as that place stays open, I’ll stay alive”: Accessing injectable opioid agonist treatment during dual public health crises
por: Jaffe, Kaitlyn, et al.
Publicado: (2023)

Changes in daily dose in open-label compared to double-blind: The role of clients’ expectations in injectable opioid agonist treatment
por: Blawatt, Sarin, et al.
Publicado: (2023)

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review
por: Adams, Alison, et al.
Publicado: (2023)

Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency
por: Marchand, Kirsten I, et al.
Publicado: (2011)

Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2023)

A chance to stop and breathe: participants’ experiences in the North American Opiate Medication Initiative clinical trial
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2014)

Dextroamphetamine Treatment for Children With Hypothalamic Obesity
por: van Schaik, Jiska, et al.
Publicado: (2021)

Dextroamphetamine Treatment in Children With Hypothalamic Obesity
por: van Schaik, Jiska, et al.
Publicado: (2022)

Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study
por: Oviedo-Joekes, Eugenia, et al.
Publicado: (2021)

Dextroamphetamine-Amphetamine Augmentation in the Treatment of Treatment-Resistant Depression
por: Small, Tyler M, et al.
Publicado: (2022)

Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review
por: Adams, Alison, et al.
Publicado: (2023)

Interactions Between Opioids and Dextroamphetamine on Locomotor Activity: Influence of an Opioid's Relative Efficacy at the Mu Receptor
por: Smith, Mark A., et al.
Publicado: (2022)

NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America
por: Gartry, Candice C, et al.
Publicado: (2009)

A critical analysis of user satisfaction surveys in addiction services: opioid maintenance treatment as a representative case study
por: Trujols, Joan, et al.
Publicado: (2014)

Central serous chorioretinopathy associated with Adderall (dextroamphetamine-amphetamine) and topical steroid use
por: Alsberge, Joseph B., et al.
Publicado: (2022)

Peer-led safer supply and opioid agonist treatment medication distribution: a case study from rural British Columbia
por: Scow, Marnie, et al.
Publicado: (2023)

Psychoactive drugs and false memory: comparison of dextroamphetamine and delta-9-tetrahydrocannabinol on false recognition
por: Ballard, Michael E., et al.
Publicado: (2011)

Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: a cohort study
por: Palis, Heather, et al.
Publicado: (2022)

Rescue Analgesia for Opioid-Dependent Individuals on Opioid Agonist Treatment during Hospitalization: Adherence to Guideline Treatment
por: Arnet, Isabelle, et al.
Publicado: (2023)

Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans
por: Smart, Kelly, et al.
Publicado: (2021)

Alcohol use in opioid agonist treatment
por: Nolan, Seonaid, et al.
Publicado: (2016)

Dextroamphetamine (but Not Atomoxetine) Induces Reanimation from General Anesthesia: Implications for the Roles of Dopamine and Norepinephrine in Active Emergence
por: Kenny, Jonathan D., et al.
Publicado: (2015)

Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study
por: Cutler, Andrew J., et al.
Publicado: (2022)

Interim opioid agonist treatment for opioid addiction: a systematic review
por: Samsó Jofra, Laura, et al.
Publicado: (2022)

Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study
por: Palis, Heather, et al.
Publicado: (2022)

Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada
por: Morin, Kristen A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i3pt07lrg3h480lvspk6ld88ds